Use this tool to help determine the recommended dose of RYBREVANT FASPRO

Use this tool to determine recommended dosing and review adverse reaction management for RYBREVANT FASPRO–based regimens. Select whether you would like to view recommended dosing or AR management, then complete the prompted inputs. All outputs are based on the Prescribing Information for RYBREVANT FASPRO and LAZCLUZE® (lazertinib).

By using this resource, you agree to the following: This RYBREVANT FASPRO Dosing Tool is being provided as is and is intended for use only by qualified healthcare providers. All calculations should be confirmed before use. Johnson & Johnson makes no claims as to the accuracy of the information contained herein. The information being provided is not a substitute for clinical judgment. Neither Johnson & Johnson nor any other party involved in the preparation or publication of this site shall be liable to you or others for any decisions made or action taken by you or others in reliance on this information.

Before initiating and during treatment, educate your patients about the importance of prophylactic strategies to help reduce the risk and severity of certain adverse reactions

View prophylactic strategiesDownload Treatment Experience Tips for patients

AR, adverse reaction; ARR, administration-related reaction; ILD, interstitial lung disease; Q2W, once every 2 weeks; Q3W, once every 3 weeks; Q4W, once every 4 weeks; VTE, venous thromboembolism.